Brii Biosciences Limited (7SS) - Net Assets
Based on the latest financial reports, Brii Biosciences Limited (7SS) has net assets worth €2.32 Billion EUR (≈ $2.72 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.36 Billion ≈ $2.76 Billion USD) and total liabilities (€36.20 Million ≈ $42.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 7SS current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.32 Billion |
| % of Total Assets | 98.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | -29.83% |
| 10-Year Change | N/A |
| Growth Volatility | 4.96 |
Brii Biosciences Limited - Net Assets Trend (2020–2025)
This chart illustrates how Brii Biosciences Limited's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Brii Biosciences Limited to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Brii Biosciences Limited (2020–2025)
The table below shows the annual net assets of Brii Biosciences Limited from 2020 to 2025. For live valuation and market cap data, see 7SS market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.32 Billion ≈ $2.72 Billion |
-10.85% |
| 2024-12-31 | €2.61 Billion ≈ $3.05 Billion |
-15.18% |
| 2023-12-31 | €3.07 Billion ≈ $3.59 Billion |
-2.70% |
| 2022-12-31 | €3.16 Billion ≈ $3.69 Billion |
-4.64% |
| 2021-12-31 | €3.31 Billion ≈ $3.87 Billion |
+290.01% |
| 2020-12-31 | €-1.74 Billion ≈ $-2.04 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Brii Biosciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 747300700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €9.85 Billion | 414.56% |
| Total Equity | €2.38 Billion | 100.00% |
Brii Biosciences Limited Competitors by Market Cap
The table below lists competitors of Brii Biosciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FELIX Gold Ltd
AU:FXG
|
$78.84 Million |
|
Flexible Solutions International Inc
NYSE MKT:FSI
|
$78.85 Million |
|
e-LITECOM CO. Ltd
KQ:041520
|
$78.88 Million |
|
Nanoform Finland Plc
HE:NANOFH
|
$78.90 Million |
|
Teads B.V.
NASDAQ:TEAD
|
$78.82 Million |
|
Resource Alam Indonesia Tbk
JK:KKGI
|
$78.81 Million |
|
Canterbury Park Holding Corporation
NASDAQ:CPHC
|
$78.80 Million |
|
Pricer AB (publ)
ST:PRIC-B
|
$78.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Brii Biosciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,656,957,000 to 2,375,689,000, a change of -281,268,000 (-10.6%).
- Net loss of 222,624,000 reduced equity.
- Share repurchases of 17,501,000 reduced equity.
- New share issuances of 539,000 increased equity.
- Other factors decreased equity by 41,682,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-222.62 Million | -9.37% |
| Share Repurchases | €17.50 Million | -0.74% |
| Share Issuances | €539.00K | +0.02% |
| Other Changes | €-41.68 Million | -1.75% |
| Total Change | €- | -10.59% |
Book Value vs Market Value Analysis
This analysis compares Brii Biosciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €-2.46 | €0.09 | x |
| 2021-12-31 | €4.64 | €0.09 | x |
| 2022-12-31 | €4.39 | €0.09 | x |
| 2023-12-31 | €4.28 | €0.09 | x |
| 2024-12-31 | €3.63 | €0.09 | x |
| 2025-12-31 | €3.29 | €0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Brii Biosciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1196.58%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.99x
- Recent ROE (-9.37%) is above the historical average (-28.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.02 Billion |
| 2021 | -124.56% | 0.00% | 0.00x | 1.08x | €-4.50 Billion |
| 2022 | -15.16% | -938.12% | 0.02x | 1.06x | €-803.77 Million |
| 2023 | -5.61% | -28335.33% | 0.00x | 1.03x | €-486.73 Million |
| 2024 | -19.13% | 0.00% | 0.00x | 1.02x | €-773.86 Million |
| 2025 | -9.37% | -1196.58% | 0.01x | 0.99x | €-460.19 Million |
Industry Comparison
This section compares Brii Biosciences Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,148,866,426
- Average return on equity (ROE) among peers: -32.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Brii Biosciences Limited (7SS) | €2.32 Billion | 0.00% | 0.02x | $78.83 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $213.00 Million | -25.91% | 0.79x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $185.23 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.06 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $19.22 Billion | -5.91% | 0.14x | $20.05 Billion |
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more